• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

PODCAST: Expert insights in managing vitiligo, part 2 on dyspigmentation

Podcast

Two of the most vexing skin conditions that dermatologists manage are melasma and vitiligo. In one condition, too much pigmentation is present because of genetic, hormonal and environmental factors. In the other, there is a lack of melanin in the skin, presumably on an autoimmune basis. In part two of this discussion on dyspigmentation conditions, Seemal Desai, M.D., who is a board-certified dermatologist, clinical assistant professor in the department of dermatology at University of Texas, Southwestern Medical Center in Dallas, and medical director of Innovative Dermatology, discusses treatment options for vitiligo with Dermatology Times editorial advisor, Dr. Norman Levine.

Two of the most vexing skin conditions that dermatologists manage are melasma and vitiligo. In one condition, too much pigmentation is present because of genetic, hormonal and environmental factors. In the other, there is a lack of melanin in the skin, presumably on an autoimmune basis. In part two of this discussion on dyspigmentation conditions, Seemal Desai, M.D., who is a board-certified dermatologist, clinical assistant professor in the department of dermatology at University of Texas, Southwestern Medical Center in Dallas, and medical director of Innovative Dermatology, discusses treatment options for vitiligo with Dermatology Times editorial advisor, Dr. Norman Levine.

READ: The full interview

Listen to more Takeaway podcasts

Best practices for encouraging medication adherence

Strategies for managing leg ulcers

Regulatory initiatives, deadlines inescapable

 

 

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.